Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lenvima in treatment-naïve metastatic NSCLC (TPS ≥ 1%)
NCT03829332Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of lenvatinib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Mar 2019; status: completed.
02
Drugs
lenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03829332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829332.